AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Standard of care chemotherapy regimen
Study NCT05800587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Standard of care chemotherapy regimen
Study NCT05212246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle Control Cream
Description: The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Study NCT05601440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: Dose and schedule will be assigned at enrolment
Study NCT05601440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose and schedule will be assigned at enrolment
Study NCT05601440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Monitoring arm
Study NCT05601440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Dose and schedule will be assigned at enrolment
Study NCT05601440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Dose and schedule will be assigned at enrolment
Study NCT05601440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3500
Description: Dose and schedule will be assigned at enrolment
Study NCT05645523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Given in to the vein (IV)
Study NCT05826535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-314
Description: CAR T-cell therapy
Study NCT06048419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Program
Description: Home program for 6 weeks (1 hr and 15 minutes per week)
Study NCT05137483 — intervention group
Intervention type: OTHER
Intervention: Functional tests
Description: We will apply upper extremity performance tests, hand grip measurements, and scales measuring fatigue and quality of life to the groups.
Study NCT06091007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Magnesium citrate of either 200mg or 400 mg will be taken by the participant with food in the morning.
Study NCT04999670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial closure method during caesarean section via pfannenstiel incision.
Description: Comparison of three different methods of fascial closure.
Study NCT06158451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Zinc oxide propolis
Description: Propolis liquid (Brazilian Green Bee Propolis Liquid Extract, Uniflora®) and Zinc oxide powder will be mixed on a glass slab with the help of a stainless -steel spatula.~• The mixing ratio of zinc oxide powder and Propolis liquid is 2:1 until a paste like consistency is reached.
Study NCT06158451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Modified triple antibiotic paste
Description: Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals, Egypt,), and clindamycin capsules 300 mg(Dalacin C™ Pfizer, Egypt).~* After the removal of enteric coating of tablets with the help of blade, the drugs are pulverized into fine powder using sterilized mortar and pestle.~* The same amount of each powdered drug (1:1:1) is mixed to form m-TAP powder which is mixed with one part of propylene glycol (P) and the same volume of macrogol (M) to form a paste like consistency
Study NCT04873466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enzyme-rich malt extract
Description: Enzyme-rich malt extract (ERME) is a by-product of the malting process in which the cereal grain barley is dried. The ingredients are 100% barley malt extract. It smells and tastes sweet, with a runny jam-like texture. Malt extract has been used as a food stuff in baking and cookery for many years, but ERME is extracted by means which retains more active enzymes, such as amylase.
Study NCT05885581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A Grow Well
Description: 1. the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~2. the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~3. the feasibility of collecting infant anthropometric data.
Study NCT05885581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm B Healthy Steps
Description: Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
Study NCT06500377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo saliva sample collection
Study NCT06500377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn breathing only meditation
Study NCT06500377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn focused attention only meditation
Study NCT06500377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn mindfulness only meditation
Study NCT06500377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Learn breathing, focused attention, and mindfulness combined meditation
Study NCT06500377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05360667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care plus plus Exergame-based multicomponent training program
Description: The program contains PRT and functional movement of the four extremities but mainly upper limbs. We will use the commercialized exergame Ringfit Adventure (RFA) to deliver the program.~RFA is a ﬁtness action role-playing game. The player advances the story while exercising as the movement of the player is linked to the main character on the screen. The movements of the player and battle actions are based on performing certain physical activities using the Ring-Con and Leg Strap. RFA itself could estimate the optimal exercise intensity for each player and performs ﬁne-tuned up-and downregulation based on these physiological feedbacks. Therefore, it has become possible to provide an appropriate amount of exercise for all generations from children to the elderly.~The standard care is applied as usual in our LTCF. (descriped as the below in the control group)
Study NCT05360667 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: The standard care in the control group is applied as usual in our LTCF, in the way of group activity, including calisthenics (that could be done in sitting position), horticultural therapy, and group activity of peace (like tabletop games). The programs are performed twice per week, about 30 to 60 minutes (depends on different activity), leading by a therapist.
Study NCT05917782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)
Description: subcutaneous injection of 2 doses on Day 1
Study NCT05917782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)
Description: subcutaneous injection of 1 dose on Day 1
Study NCT05917782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)
Description: subcutaneous injection of 2 doses on Day 1
Study NCT05738590 — intervention group
Intervention type: PROCEDURE
Intervention: muscle biopsy
Description: true cut needle biopsy
Study NCT05526950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: CytoSorb
Description: Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
Study NCT05371444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training with restriction of the DoF
Description: The intervention is based in the training of a single DoF of the upper extremity with restriction of the rest DoF of the arm and trunk that aren't being trained being restrained by an exoskeleton
Study NCT05371444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training without restriction of the DoF
Description: The intrevention is based in the training of the upper extremity movements without the restriction of DoF
Study NCT05034055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab / tiragolumab
Description: All patients will receive 1200mg atezolizumab administered by IV infusion on Day 1 of each 21-day cycle after completion of stereotactic body radiotherapy (SBRT) for 21(+5) days. No escalations or reductions in the dose of the investigational product will be allowed.Following the administration of atezolizumab, patients will receive 600mg tiragolumab administered by IV infusion on Day 1 of each 21-day cycle. The tiragolumab dose is fixed and is not dependent on body weight.
Study NCT05427643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: study group
Description: dental implant procedure under local anesthesia
Study NCT05427643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: dental implant procedure under local anesthesia
Study NCT06074952 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)
Description: Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.
Study NCT04313972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose naltrexone
Description: 2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks
Study NCT04313972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
Study NCT01616602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: Patients were asked to lay on their abdomen for their elective colonoscopy.
Study NCT01616602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Position
Description: The traditional left-lateral decubitus position
Study NCT05755815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrolaminar block
Description: A high-frequency 12 MHz linear ultrasound probe will be used, patients will receive bilateral ultrasound-guided retrolaminar plane block with 20 mL of bupivacaine 0.25%. Their spines will be palpated from the vertebra prominens caudally to T7 and point will be marked to identify the spinous processes, which will be confirmed by ultrasound through counting from T12 with the characteristic last rib attached to its transverse process upward to the T7 lamina. The linear high frequency transducer (6-13 MHz) will be placed in the parasagittal plane one cm lateral to the midline. The needle will be inserted in the in-plane view of the ultrasound probe and will be advanced from downward to upward to target the T7 posterior lamina surface at an angle of 90˚ to the skin until the needle tip will be contacted the posterior surface of targeted lamina . After negative aspiration, 20 mL of bupivacaine 0.25% will be injected. The procedure was repeated following the same steps on the other side.
Study NCT05755815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peritoneal block
Description: before giving an incision for the ports, 20 ml of 0.25% bupivacaine will be infiltrated subcutaneously over the port sites (6 ml will be infiltrated around each midline port site and 4 ml will be infiltrated around at the lateral port sites) and at the end of surgery and before the removal of trocars, 20 ml of 0.25% bupivacaine diluted in normal saline will be instilled by the surgeon intraperitoneally at gallbladder bed and under domes of both diaphragms under direct vision with a separate catheter passed through one of the trocars.. The pressure of the gas insufflation was kept within 10-12 mm Hg in all patients. At the end of surgery, CO2 was evacuated, and intraperitoneal anesthetic solution was left in situ.
Study NCT05606237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Red Light Therapy Device
Description: The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
Study NCT04704622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
Study NCT04704622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
Study NCT04704622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
Study NCT01113606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Obagi New-Derm System
Study NCT01113606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT05525871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrates and Citrulline Malate
Description: Female soccer players should consume the experimental product for 30 days to evaluate the efficacy of a sports supplement high in nitrates combined with citrulline malate in the improvement of performance in high-intensity intermittent exercise.~high intensity
Study NCT05525871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: Fruit puree
Study NCT05992805 — intervention group
Intervention type: OTHER
Intervention: N/A - non-interventional study
Description: N/A - non-interventional study. Data collection only.
Study NCT05709808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio-taping
Description: kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance
Study NCT05709808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
Study NCT05709808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
Study NCT05709808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed kinesiotape plus exercises
Description: kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance. A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
Study NCT05874531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: End-expiratory occlusion test
Description: 15 seconds end-expiratory occlusion
Study NCT06454084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine Chloride
Description: Vasodilator solution
Study NCT05384041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
Description: The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
Study NCT05384041 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
Description: The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
Study NCT04539093 — intervention group
Intervention type: OTHER
Intervention: Exposure of interest - Use of left ventricular assist device (LVAD)
Description: Mechanical circulatory support devices such as left ventricular assist device is used as a treatment option for patients with end-stage heart failure.
Study NCT05728788 — intervention group
Intervention type: DRUG
Intervention: Antitumor drugs
Description: Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
Study NCT05353790 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meals + snacks: control
Description: 8 weeks meal plans matched in calories (but not macronutrients or fiber) equivalent to 1 avocado + 1 cup of mango per day
Study NCT05353790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals + snacks: Avocado mango
Description: 8 weeks meal plans provide1 avocado + 1 cup of mango per day
Study NCT06242119 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: J-PET scan
Description: Diagnostic Test: Positron-Emission Tomography Imaging Examination of radiation distribution in the patient body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA, \[18F\]choline or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
Study NCT04551040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin
Description: Terazosin 1 mg oral capsule
Study NCT06313892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based Exercise
Description: The participants in the study group will be given an online personalized exercise program at home in non dialysis days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
Study NCT05676203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ADT (androgen deprivation therapy)
Description: as prescribed by the treating physician.
Study NCT05676203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard ADT (androgen deprivation therapy)
Description: as prescribed by the treating physician.
Study NCT05676203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Darolutamide
Description: 2x600 mg/d as prescribed by the treating physician
Study NCT05676203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Darolutamide
Description: 2x600 mg/d as prescribed by the treating physician
Study NCT05676203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel
Study NCT05676203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study NCT05503771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISA-MI
Description: Parents seen by clinicians randomized to the intervention group will complete the Infant Sleep Assessment (ISA), either prior to their visit using MyChart (Epic patient portal) or on a tablet computer in the exam room while they wait for their clinician; 2) a Clinical Decision Support (CDS) smart form is created in the EMR based on the assessment results, with risks and MI-informed strategies highlighted; this information will be derived from a pre-programmed algorithm and theory-based, tailored communication strategies and messages; 3) the clinician uses the CDS smart form to guide counseling with the parent during the visit, applying their training in MI-informed counseling skills; and 4) Clinician gives the parent an After Visit Summary (AVS) from the EMR (or informs them that they can access the AVS in MyChart if the parent or other caregivers use the patient portal, MyChart), which summarizes and reinforces the safe sleep counseling.
Study NCT05503771 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: Parents seen by clinicians randomized to the control group will receive the usual practice that pediatric residents are taught which follows the American Academy of Pediatrics (AAP) Bright Futures Health Supervision Guidelines and includes age and developmentally based anticipatory guidance. As part of their training, residents receive formal teaching on core aspects of providing primary care to infants, including the AAP recommendations on safe sleep. This includes the recommended ABCS: babies should sleep Alone (no objects or people), on their Back (supine), in a Crib (or safe alternative including portable crib or bassinet), and in a Smoke-free environment.